Alemtuzumab is administered intravenously at a dosage of 12 mg/day on days 1–5 of the first year and days 1–3 of the second year. Clinical trials: a first Phase III trial (comparison of alemtuzumab and Rebif® efficacy in MS – CARE-MS I) with 581 patients with RRMS without preceding disease-modifying therapy compared alemtuzumab (at a dosage of 12 mg/day on days 1–5 of the first year and days 1–3 of the second year) to IFN-β 1a (3 × 44 μg/week) for 2 years [65]. Alemtuzumab reduced the relapse rate by 55%

compared to IFN-β 1a (P < 0·0001). The proportion of patients with confirmed disability progression was reduced from 11% (IFN-β-1a) to 8% (alemtuzumab, P = 0·22) selleck chemicals [65]. A second Phase III trial (comparison of alemtuzumab and Rebif® efficacy in MS – CARE-MS II) with 667 patients with RRMS with sustained disease activity despite prior disease-modifying therapy compared alemtuzumab at a dosage of 12 mg/day on days 1 to 5 of the first year and days 1 to

3 of the second year to IFN-β-1a (3 × 44 μg/week) for 2 years [66]. Alemtuzumab reduced relapse rate by 49% (P < 0·0001) and the proportion of patients with confirmed diability progression by 42% (P = 0·008) compared to IFN-β-1a [66]. Based on the efficacy of alemtuzumab in the treatment of RRMS, this treatment is now being evaluated in patients with CIDP. In a small study, four of seven CIDP patients showed improvement following alemtuzumab; two of

these achieved complete remission [67]. An open-label Phase IV clinical trial is currently being initiated to evaluate DNA ligase the impact of alemtuzumab in patients with CIDP (an open-label BGB324 purchase trial of alemtuzumab in CIDP). Adverse effects: in both Phase III clinical trials, most frequent adverse events with alemtuzumab were infusion reactions and infections (infections of the upper respiratory tract, urinary tract, sinusitis and herpes simplex infections). There were no treatment-associated life-threatening or fatal infections with alemtuzumab treatment. Autoimmune thyroiditis occurred in 16% of patients treated with alemtuzumab and autoimmune thrombocytopenia in 1%, with one fatal outcome. Secondary B cell-mediated autoimmunity is an established phenomenon that occurs in patients with MS treated with alemtuzumab. These complications were detected by careful study-monitoring and treated accordingly. Rituximab is a chimeric antibody specifically binding to the CD20 antigen on the surface of B cells. It depletes these cells by inducing complement-mediated cell lysis. Preparations and administration: rituxmab (MabThera®, Rituxan®) is currently approved for the treatment of patients with non-Hodgkin lymphoma, rheumatoid arthritis and anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitits. Rituximab is commonly administered i.v. either at a dose of 1000 mg on days 1 and 15, or 375 mg/m2 in four weekly doses.